Results 271 to 280 of about 1,600,059 (380)

The risks of major head and neck surgery in the aged population [PDF]

open access: bronze, 1977
William F. McGuirt   +3 more
openalex   +1 more source

Presbycusis: Pathology, Signal Pathways, and Therapeutic Strategy

open access: yesAdvanced Science, EarlyView.
In ARHL, the stria vascularis, acting as a cochlear battery, gradually loses its ability to maintain the endocochlear potential, leading to impaired hair cell function and progressive hearing loss. Single‐cell sequencing reveals age‐related cellular changes in the cochlea, providing insights into the underlying mechanisms of aging and potential ...
Xiaoxu Zhao   +12 more
wiley   +1 more source

HPV-Driven Head and Neck Cancer: The European Perspective. [PDF]

open access: yesViruses
Golusiński W   +3 more
europepmc   +1 more source

Paragangliomas of the head and neck region.A clinical study of 69 patients [PDF]

open access: bronze, 1977
Ernest E. Lack   +3 more
openalex   +1 more source

Rational Design of Inner Ear Drug Delivery Systems

open access: yesAdvanced Science, EarlyView.
Hearing loss is a common disease affecting many people, and inner ear lesions are one of the most important causes. This review focuses on the treatment of inner ear hearing loss by drug delivery systems. It includes the current methods and technologies developed, and it predicts possible directions.
Xiayidan Maimaitikelimu   +5 more
wiley   +1 more source

Sex Differences in Head and Neck Carcinoma - A Retrospective Study on 1115 Head and Neck Carcinoma Patients in Austria. [PDF]

open access: yesJ Otolaryngol Head Neck Surg
Kofler B   +11 more
europepmc   +1 more source

175. Pursuit Motion in Patients with Head and Neck Injuries

open access: bronze, 1967
Yoshinao HUKADO   +3 more
openalex   +2 more sources

Combination therapy of advanced head and neck cancer.Induction of remissions with diamminedichloroplatinum (II), bleomycin and radiation therapy [PDF]

open access: bronze, 1978
Victor L. Randolph   +6 more
openalex   +1 more source

A CMTM6 Nanobody Overcomes EGFR‐TKI Resistance in Non‐Small Cell Lung Cancer

open access: yesAdvanced Science, EarlyView.
Overcoming EGFR‐TKI resistance remains a critical challenge in NSCLC treatment. This study identifies CMTM6 as a key regulator of EGFR stability and demonstrates that a novel anti‐CMTM6 nanobody disrupts the CMTM6‐EGFR interaction. Targeting CMTM6 restores EGFR degradation, suppresses tumor growth, and confers therapeutic benefit in both CDX and PDX ...
Lu Xia   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy